Praxis raises ~$161.7M in stock/warrant offering; funds operations into 2026

Praxis Precision Medicines, Inc.

Public offering of 3,168,275 shares of common at $35.50 and pre-funded warrants for 1,056,725 shares at $35.4999.
Underwriters exercised option to purchase an additional 633,750 shares; total net proceeds ~$161.7M.
Proceeds to fund Phase 3 studies for ulixacaltamide and clinical development of PRAX-628, PRAX-562, PRAX-222.
Company believes net proceeds plus existing cash will fund operating expenses and capex into 2026.
Closing expected January 16, 2024, subject to customary conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.